iSpecimen Inc. reports developments tied to its online marketplace for human biospecimens, which connects life science researchers with a network of healthcare specimen providers. Company updates cover biospecimen sourcing for research projects, supplier-network responsiveness, direct-to-customer shipping, and marketplace technology used to match customer requests with available inventory.
Recurring news themes include AI-assisted inventory matching, SalesStack marketplace integration, respiratory and other specimen procurement, international sourcing relationships, and capital-structure actions such as the completed reverse stock split of ISPC common stock.
iSpecimen (Nasdaq: ISPC) announced the addition of a reference lab in New York to enhance its supplier capabilities for COVID-19 research. This lab can sequence hundreds of COVID-19 positive swabs weekly, aiding in the identification of variants like Omicron and Delta. iSpecimen has provided over 15,000 specimens for more than 200 COVID-related projects since the pandemic's onset and has collaborated with the CDC by supplying positive and negative serum samples. This expansion supports researchers' needs for variant identification in the ongoing fight against COVID-19.
iSpecimen Inc. (Nasdaq: ISPC) announced participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Christopher Ianelli will present on-demand starting January 10 at 7:00 a.m. ET. iSpecimen provides an online marketplace connecting life scientists with healthcare providers for biospecimens.
For more details, contact H.C. Wainwright or KCSA Strategic Communications at iSpecimen@kcsa.com.
iSpecimen Inc. (NASDAQ: ISPC) announced a significant expansion of its global supplier network, with 25% of new suppliers located outside the U.S. This growth enhances the iSpecimen Marketplace, which now includes over 200 suppliers. The company aims to meet increasing demands for biospecimens in Europe and Asia-Pacific, supporting various medical research fields. Key benefits include improved access to biospecimens and addressing worldwide research needs. The iSpecimen Marketplace streamlines procurement for life science researchers, tackling the shortage of quality biospecimens.
iSpecimen (Nasdaq: ISPC) announced the expansion of its global biospecimen provider network to support research on neurological disorders, affecting approximately one billion people worldwide. Over the past ten months, it has added over a dozen sample providers, supplying biospecimens such as cerebrospinal fluid and other biofluids. iSpecimen can now provide samples from COVID-19 patients exhibiting neurological symptoms, assisting researchers facing biospecimen shortages. This initiative follows National Epilepsy and Alzheimer’s Awareness Months, aiming to facilitate medical discoveries related to these conditions.
iSpecimen Inc. (Nasdaq: ISPC) has successfully closed a private placement, raising approximately $21 million by selling 1,749,999 shares of common stock and warrants to purchase 1,312,500 shares. Each share was sold at a price of $12.00, accompanied by three-quarters of a warrant, which has an exercise price of $13.00 and a term of five and a half years. The private placement was managed by ThinkEquity. The securities offered will not be registered under the Securities Act, and iSpecimen plans to file a registration statement with the SEC for resale purposes.
iSpecimen (Nasdaq: ISPC) has announced a definitive agreement for a private placement to sell 1,749,999 shares of common stock and warrants, expecting to raise approximately $21.0 million in gross proceeds. Each share is priced at $12.00, accompanied by warrants exercisable at $13.00 per share. The placement is set to close on December 1, 2021, subject to customary conditions. The securities will not be registered under the Securities Act and will require a registration statement for resale. This transaction aims to strengthen the company's liquidity and financial position.
iSpecimen (Nasdaq: ISPC), a marketplace for human biospecimens, has secured contracts to support advanced COVID-19 research focusing on transmissibility and variant outcomes. The company has partnered with various research organizations over the past ten months, providing samples like nasal swabs and blood products. Notably, iSpecimen has supplied 600 positive and 100 negative serum samples to the CDC for antibody monitoring. Their work extends to military and private organizations, facilitating custom COVID-19 collections across diverse demographics to aid ongoing studies.
iSpecimen reported strong financial results for Q3 2021, with revenue increasing by 21% to $2.7 million, driven by expanding sales efforts and a growing user base. The company's nine-month revenue surpassed $8.6 million, a 57% increase compared to 2020. Notably, unique suppliers increased to 197 and registered users in the marketplace grew 30% year-over-year. Despite increasing general and administrative expenses to $1.7 million, the net loss reduced to approximately $1.1 million. iSpecimen aims to broaden its offerings and enhance its technology moving forward.
iSpecimen Inc. (Nasdaq: ISPC) announces participation in two virtual conferences in November 2021: A.G.P.'s Biotech & Specialty Pharma Conference on November 10 and the 12th Annual Craig-Hallum Alpha Select Conference on November 16. These events will provide opportunities for one-on-one meetings with management. iSpecimen specializes in connecting life scientists to human biospecimens through a unique online marketplace and cloud-based technology, enhancing medical discovery efforts. For more details, visit www.ispecimen.com.
iSpecimen Inc. (NASDAQ: ISPC) will announce its third quarter financial results on November 4, 2021, before market open. The conference call is scheduled for 8:30 a.m. ET, featuring remarks from CEO Christopher Ianelli, CFO Tracy Curley, and COO Jill Mullan. Interested individuals can join the call via toll-free numbers or access a replay until November 18, 2021. The company provides an online marketplace for human biospecimens, connecting scientists with healthcare providers for medical research.